The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 488-495

  Xu, Dapeng ^a   Allsop, Stephen A ^a   Witherspoon, Sam M ^a   Snider, Jared L ^b,c   Yeh, Jen Jen ^b,c   Fiordalisi, James J ^b,c   White, Catherine D ^d   Williams, Daniel ^a   Cox, Adrienne D ^b,c   Baines, Antonio T ^a,b,c  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NORTH CAROLINA A AND T STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; K RAS PROTEIN; MATRIGEL; NESTIN; PROTEIN BAD; PROTEIN KINASE PIM 1; SERINE; SHORT HAIRPIN RNA;

ARTICLE; CANCER MODEL; CANCER RESISTANCE; CANCER TISSUE; CARCINOMA CELL; CELL GROWTH; CELL INVASION; CELL LEVEL; CELL PROLIFERATION; CELL TRANSFORMATION; CLONOGENIC ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS CARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; RADIATION TOLERANCE; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 79953678390     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr007     Document Type: Article

References (44)

1. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, pp. 18-19.
2. Warshaw, A.L. et al. (1992) Pancreatic carcinoma. N. Engl. J. Med., 326, 455-465.
3. Malumbres, M. et al. (2003) RAS oncogenes: the first 30 years. Nat. Rev. Cancer, 3, 459-465.
4. Yeh, J.J. et al. (2007) Targeting signal transduction in pancreatic cancer treatment. Expert. Opin. Ther. Targets, 11, 673-694.
5. Campbell, P.M. et al. (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res., 67, 2098-2106.
6. Singh, A. et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell, 15, 489-500.
7. Baines, A.T. et al. (2006) Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol., 407, 556-574.
8. Fleming, J.B. et al. (2005) Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res., 3, 413-423.
9. Brummelkamp, T.R. et al. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243-24.
10. Qian, J. (2005) In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res., 65, 5045-5053.
11. Bachmann, M. et al. (2005) The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol., 37, 726-730.
12. Wang, Z. et al. (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci., 2, 167-179.
13. Brault, L. et al. (2010) PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 95, 1004-1015.
14. Qian, K.C. et al. (2005) Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J. Biol. Chem., 280, 6130-6137.
15. Aho, T.L. et al. (2004) Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett., 571, 43-49.
16. Morishita, D. et al. (2008) Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res., 68, 5076-5085.
17. Shah, N. et al. (2008) Potential roles for the PIM1 kinase in human cancer -a molecular and therapeutic appraisal. Eur. J. Cancer, 44, 2144-2151.
18. Chen, J. et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene, 28, 2581-2592.
19. Reiser-Erkan, C. et al. (2008) Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther., 7, 1352-1359.
20. Chen, J. et al. (2009) Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol., 175, 400-411.
21. Li, Y.Y. et al. (2006) Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res., 66, 6741-6747.
22. Moffat, J. et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell, 124, 1283-1298.
23. Grana, T.M. et al. (2002) Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogenactivated protein kinase/extracellular signal-regulated kinase kinaseindependent signaling pathways. Cancer Res., 62, 4142-4150.
24. Macdonald, A. et al. (2006) Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol., 7, 1.
25. Freedman, V.H. et al. (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell, 3, 355-359.
26. Abiatari, I. et al. (2009) Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther., 8, 1494-1504.
27. Dreissigacker, U. et al. (2006) Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal., 18, 1156-1168.
28. Gupta, A.K. et al. (2001) The Ras radiation resistance pathway. Cancer Res., 61, 4278-4282.
29. McKenna, W.G. et al. (2003) Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer, 38, 330-338.
30. Bernhard, E.J. et al. (2000) Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res., 60, 6597-6600.
31. Hezel, A.F. et al. (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev., 20, 1218-1249.
32. Brunner, T.B. et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res., 65, 8433-8441.
33. Kidd, A.R. 3rd et al. (2010) Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys., 78, 205-212.
34. Peltola, K. et al. (2009) Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia, 11, 629-636.
35. Chen, W.W. et al. (2005) Pim family kinases enhance tumor growth of prostate cancer cells. Mol. Cancer Res., 3, 443-451.
36. Grundler, R. et al. (2009) Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med., 206, 1957-1970.
37. Dai, H. et al. (2005) Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate, 65, 276-286.
38. Tanaka, S. (2009) Pim-1 activation of cell motility induces the malignant phenotype of tongue carcinoma. Mol. Med. Report, 2, 313-318.
39. Shaw, A.Y. et al. (2009) Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J. Pharmacol. Exp. Ther., 331, 636-647.
40. Xia, Z. et al. (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem., 52, 74-86.
41. Beharry, Z. et al. (2009) Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther., 8, 1473-1483.
42. Chen, L.S. et al. (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 114, 4150-4157.
43. Mumenthaler, S.M. et al. (2009) Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther., 8, 2882-2893.
44. Choudhary, C. et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell, 36, 326-339.